![Mark Bodmer](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Bodmer
Director Ejecutivo en
Nucleome Therapeutics Ltd.
.
Perfil
Mark W.
Bodmer is currently Chief Executive Officer at Nucleome Therapeutics Ltd. Former positions include Chief Executive Officer at Biotica Technology Ltd., Hexagen Plc, and Lorantis Ltd. (1999–2004); Director at The Bioindustry Association (2015–2016); Principal at The Wellcome Trust Ltd., Schroder Ventures Holdings Plc, Apax, and JPMorgan Partners Europe; Vice President-New Medicines Therapeutics at UCB SA (2012–2016); Senior Vice President-Research & Development at Incyte Pharmaceuticals, Inc. (1998–1999); and Chief Scientific Officer, President-R&D at Evelo Biosciences, Inc. (2016–2024).
Education includes undergraduate and doctorate degrees from the University of Cambridge.
Cargos activos de Mark Bodmer
| Empresas | Cargo | Inicio |
|---|---|---|
Nucleome Therapeutics Ltd.
 Nucleome Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecular drugs for autoimmune diseases | Director Ejecutivo | - |
Antiguos cargos conocidos de Mark Bodmer.
| Empresas | Cargo | Fin |
|---|---|---|
| EVELO BIOSCIENCES, INC. | Director Técnico/Científico/I+D | 01/02/2024 |
The Bioindustry Association
 The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services Operates as a association to encourage and promote bioscience sector | Director/Miembro de la Junta | 01/04/2016 |
| UCB | Corporate Officer/Principal | 01/04/2016 |
Lorantis Ltd.
 Lorantis Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | Presidente | 01/01/2004 |
Incyte Pharmaceuticals, Inc.
 Incyte Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Director Técnico/Científico/I+D | 01/01/1999 |
Formación de Mark Bodmer.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
31
Relaciones de 1er grado
13
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 13 |
|---|---|
The Wellcome Trust Ltd.
 The Wellcome Trust Ltd. Investment Trusts/Mutual FundsMiscellaneous Provides welfare and charitable services | Miscellaneous |
Biotica Technology Ltd.
 Biotica Technology Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
UCB SA
 UCB SA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
Schroder Ventures Holdings Plc
 Schroder Ventures Holdings Plc Financial ConglomeratesFinance Private equity firm | Finance |
Incyte Pharmaceuticals, Inc.
Incyte Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Hexagen Plc
 Hexagen Plc BiotechnologyHealth Technology Develops technology for discovery of single nucleotide polymorphisms | Health Technology |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lorantis Ltd.
Lorantis Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | Health Technology |
Apax
 Apax Home FurnishingsConsumer Durables Manufactures furniture | Consumer Durables |
JPMorgan Partners Europe
 JPMorgan Partners Europe Financial ConglomeratesFinance Private equity group | Finance |
The Bioindustry Association
The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services Operates as a association to encourage and promote bioscience sector | Commercial Services |
Evelo Biosciences, Inc.
 Evelo Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapeutics for small intestine related diseases | Health Technology |
Nucleome Therapeutics Ltd.
Nucleome Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecular drugs for autoimmune diseases | Health Technology |
- Bolsa de valores
- Insiders
- Mark Bodmer
